Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome

Overview

Journal Microorganisms

Specialty Microbiology

Date 2019 Jan 13

PMID 30634669

Citations 15

Authors

Simona Buelli

Carlamaria Zoja

Giuseppe Remuzzi

Marina Morigi

Affiliations

Soon will be listed here.

Abstract

Shiga toxin (Stx)-producing (STEC) infections have become a threat to public health globally because of the severe illnesses that they can trigger, such as hemorrhagic colitis and the post-diarrheal hemolytic uremic syndrome (HUS), characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney failure. Glomerular endothelial cells are primary targets of Stx which, after binding to its specific receptor globotriaosylceramide, upregulates proinflammatory proteins involved both in the recruitment and adhesion of leukocytes and thrombus formation at the site of endothelial injury. In this review, we discuss the role of complement activation in promoting glomerular microvascular dysfunction, providing evidence from experimental models and patients with STEC-HUS. Within the glomerulus, an important target for Stx-induced complement activation is the podocyte, a cell type that is in close contact with endothelial cells and participates in maintaining the filtration barrier. Recently, podocyte injury and loss have been indicated as potential risk factors for long-term renal sequelae in patients with STEC-HUS. Therapeutic approaches targeting the complement system, that may be useful options for patients with STEC-HUS, will also be discussed.

Citing Articles

The role of the complement system in Shiga toxin-associated hemolytic uremic syndrome.

Bocanegra V, Luna M, Costantino V, Lorenzo A, Marino R, Miatello R Pediatr Nephrol. 2025; .

PMID: 39792253 DOI: 10.1007/s00467-024-06629-6.

Two cases of typical HUS in adults treated with an anti-C5 monoclonal antibody: a new perspective?.

Stambolliu E, Giannou P, Nomikou E, Aggelis G, Petras D J Nephrol. 2024; .

PMID: 39073701 DOI: 10.1007/s40620-024-02034-2.

Platelets in Renal Disease.

Gomchok D, Ge R, Wuren T Int J Mol Sci. 2023; 24(19).

PMID: 37834171 PMC: 10572297. DOI: 10.3390/ijms241914724.

Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities.

Antonucci L, Thurman J, Vivarelli M Pediatr Nephrol. 2023; 39(5):1387-1404.

PMID: 37733095 DOI: 10.1007/s00467-023-06120-8.

Constipation and hemolytic uremic syndrome.

Crawford B, Strebeck P, Saccente S Pediatr Nephrol. 2023; 39(2):603-607.

PMID: 37474629 DOI: 10.1007/s00467-023-06093-8.

References

Taylor Jr F, Tesh V, DeBault L, Li A, Chang A, Kosanke S . Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol. 1999; 154(4):1285-99. PMC: 1866558. DOI: 10.1016/S0002-9440(10)65380-1. View

Hughes A, Stricklett P, Schmid D, Kohan D . Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int. 2000; 57(6):2350-9. DOI: 10.1046/j.1523-1755.2000.00095.x. View

Walport M . Complement. First of two parts. N Engl J Med. 2001; 344(14):1058-66. DOI: 10.1056/NEJM200104053441406. View

Hughes A, Stricklett P, Kohan D . Shiga toxin-1 regulation of cytokine production by human glomerular epithelial cells. Nephron. 2001; 88(1):14-23. DOI: 10.1159/000045953. View

Ruggenenti P, Noris M, Remuzzi G . Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001; 60(3):831-46. DOI: 10.1046/j.1523-1755.2001.060003831.x. View

Kim Y, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L . Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int. 2001; 60(3):957-68. DOI: 10.1046/j.1523-1755.2001.060003957.x. View

Morigi M, Galbusera M, Binda E, Imberti B, Gastoldi S, Remuzzi A . Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood. 2001; 98(6):1828-35. DOI: 10.1182/blood.v98.6.1828. View

Rutjes N, Binnington B, Smith C, Maloney M, Lingwood C . Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 2002; 62(3):832-45. DOI: 10.1046/j.1523-1755.2002.00502.x. View

Zoja C, Angioletti S, Donadelli R, Zanchi C, Tomasoni S, Binda E . Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int. 2002; 62(3):846-56. DOI: 10.1046/j.1523-1755.2002.00503.x. View

10.

Schraufstatter I, Trieu K, Sikora L, Sriramarao P, DiScipio R . Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol. 2002; 169(4):2102-10. DOI: 10.4049/jimmunol.169.4.2102. View

11.

Ergonul Z, Clayton F, Fogo A, Kohan D . Shigatoxin-1 binding and receptor expression in human kidneys do not change with age. Pediatr Nephrol. 2003; 18(3):246-53. DOI: 10.1007/s00467-002-1025-9. View

12.

Matussek A, Lauber J, Bergau A, Hansen W, Rohde M, Dittmar K . Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood. 2003; 102(4):1323-32. DOI: 10.1182/blood-2002-10-3301. View

13.

Monsinjon T, Gasque P, Chan P, Ischenko A, Brady J, Fontaine M . Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 2003; 17(9):1003-14. DOI: 10.1096/fj.02-0737com. View

14.

Garg A, Suri R, Barrowman N, Rehman F, Matsell D, Rosas-Arellano M . Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. 2003; 290(10):1360-70. DOI: 10.1001/jama.290.10.1360. View

15.

OBrien A, Tesh V, Donohue-Rolfe A, Jackson M, Olsnes S, Sandvig K . Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol. 1992; 180:65-94. DOI: 10.1007/978-3-642-77238-2_4. View

16.

Robson W, Leung A, Fick G, McKenna A . Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron. 1992; 62(3):296-9. DOI: 10.1159/000187063. View

17.

Albrecht E, Chinnaiyan A, Varambally S, Kumar-Sinha C, Barrette T, Sarma J . C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol. 2004; 164(3):849-59. PMC: 1613300. DOI: 10.1016/S0002-9440(10)63173-2. View

18.

Ikeda M, Ito S, Honda M . Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin. Pediatr Nephrol. 2004; 19(5):485-9. DOI: 10.1007/s00467-003-1395-7. View

19.

Louise C, Obrig T . Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun. 1992; 60(4):1536-43. PMC: 257028. DOI: 10.1128/iai.60.4.1536-1543.1992. View

20.

Noris M, Remuzzi G . Hemolytic uremic syndrome. J Am Soc Nephrol. 2005; 16(4):1035-50. DOI: 10.1681/ASN.2004100861. View